Abstract
Molsidomine drugs corvaton and sidnopharm were given as monotherapy to 95 coronary heart disease (CHD) patients with circulatory defects. Positive effects on coronary and myocardial reserves were reported in 70,8 and 58.3%, 68,4 and 56.8% of cases, respectively. Corvaton caused side effects in 3.1%, sidnopharm in 12.5% of the patients. Corvaton is more potent as regards hemodynamics, myocardial contractility and reserves.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Coronary Circulation / drug effects*
-
Drug Evaluation
-
Female
-
Heart / drug effects*
-
Heart / physiopathology
-
Heart Failure / drug therapy*
-
Heart Failure / etiology
-
Heart Failure / physiopathology
-
Hemodynamics / drug effects
-
Humans
-
Male
-
Middle Aged
-
Molsidomine / therapeutic use*
-
Myocardial Ischemia / complications
-
Myocardial Ischemia / drug therapy*
-
Myocardial Ischemia / physiopathology
-
Tablets